|3rd April 2020
The choices made by the research and development team are central to the commercialisation of every pharma product, for example, about evidence generation during clinical trials.
Despite this, the commercial team’s involvement in pharmaceutical launches traditionally only begins in earnest during late Phase II or Phase III, after the release of the evidence and much of the value of the drug has been fixed.
Only then does the team seek to capitalise on the already defined profile of a product. However, to successfully launch a drug in the complex and hypercompetitive environment of today, pharma needs to think differently.
Success is dependent on considering where the product fits into the market today and tomorrow. This means pre-empting the competition, carving out a differentiated story and building the capability to deliver it. For the best results, start that process in the early stages of product development, while the evidence generation strategy is underway.
Blue Latitude Health speaks to Mark Assenti, Managing Consultant and the Head of our Early Stage Strategy service, about how this new way of thinking breeds successful product launches.
MA: The pharma market is more competitive than ever before and the way we interact with customers – including the patient – is changing. On top of this, there are new practices in the way healthcare is organised. The market is evolving, so it’s now more important than ever to assess the portfolio early on to optimise value.
From portfolio acquisitions to scientific communications, Early Stage Strategies encompass the big and the small. Ultimately, an Early Stage Strategy facilitates decision making. It involves looking at the market through both a commercial and medical lens and then developing a strategy for addressing the evolving challenges, based on the value of the product and portfolio. By taking this approach, you don’t just increase your chances of delivering at launch, but you also stake your claim in future markets.
|22nd June 2020
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
|9th June 2020
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.